Trial on Azheimer's disease vaccine to use PET tracer

10/11/2009 | Pharmaceutical Business Review Online

A Phase I study on ACI-24, a vaccine for Alzheimer's disease being developed by AC Immune, will use PET tracer candidate florbetaben from Bayer Schering Pharma to image beta-amyloid accumulation in patients' brains. "The adoption of a diagnostic imaging substance visualizing the deposition of beta-amyloid that is targeted by our vaccine can be an important parameter for dose selection, and will provide useful complementary data," AC Immune CEO Andrea Pfeifer said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX